Agenus

#9289

Rank

$68.33M

Marketcap

United States

Country

Leadership team

Dr. Garo H. Armen Ph.D. (Founder, Exec. Chairman & CEO)

Ms. Christine M. Klaskin (VP of Fin., Principal Financial Officer & Principal Accounting Officer)

Dr. Steven J. O'Day M.D., Ph.D. (Chief Medical Officer)

Products/ Services

Biotechnology, Medical, Medical Device, Therapeutics

Number of Employees

100 - 500

Headquarters

Lexington, Massachusetts, United States

Established

1994

Company Registration

SEC CIK number: 0001098972

Revenue

20M - 100M

Traded as

AGEN

Social Media

URL

https://www.agenusbio.com

Overview

Location

Recognition and Award

References

Summary

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

History

Agenus was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators and a platform to rapidly and efficiently discover new antibodies.

In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant In April 2014, Agenus inked a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.

Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.

Mission

Agenus’ mission is to develop novel therapies to activate and modulate the immune system which in turn should improve the outcome of disease, such as cancer and other infectious disorders.

Vision

Agenus’ vision is to create and develop immuno-oncology therapies and treatments that will improve the care and outcome of patients with cancer and other serious diseases.

Key Team

Dr. Jennifer S. Buell Ph.D. (Pres & CEO of MiNK Therapeutics)

Ms. Tracy Mazza Clemente (Chief People Officer)

John Castle (Head of Translational Medicine & Bioinformatics)

Craig Winter (Chief Information Officer)

Ms. Julie DeSander (Chief Bus. Officer)

Regina Grebla Ph.D. (VP of Investor Relations & Communications)

Ms. Robin E. Abrams J.D. (Chief Legal Officer)

Recognition and Awards

Agenus has been the recipient of numerous awards, including a Corporate & Dr. Jack Cuzick Award for their work in 2011 to finally bring their vaccine, Prophage, to the patients. The company has also been recognized by the European Biotechnology Network as an Innovator in Oncology and as an InVenta Award recipient in 2013 for commercializing their balstilimab drug.